• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Table 31Change in HbA1c for pioglitazone compared with metformin in adults with type 2 diabetes

Author, year
Quality
InterventionHbA1c (%)change from baseline (mean, SD) for pioglitazoneHbA1c change from baseline (mean, SD) for active controlP value of between- group difference
Kato 2009140Pio 15 mg daily
Metformin 500 mg daily
−1.05 (NR)−0.83 (NR)NSD
Kusaka 2008136
Japan
Fair
Pio 15 mg daily (women); 30 mg daily (men)
Metformin 750 mg daily
−1.1 (NR)−1.0 (NR)NR
Perez, 2009139Pio 30mg daily
Metformin 1700 daily
−0.96 (NR)−0.99 (NR)NSD
Schernthaner 2004137
Multinational
Good
Pio 30–45 mg daily
Metformin 850–2,550 mg daily
−1.41 (0.04)−1.50 (0.04)NSD
Sharma 2006132
Fair
Pio 15–30 mg daily
Metformin 1000–2000 mg daily
−0.42 (NR)−0.47 (NR)0.43
Van der Meer 2009138
Netherlands
Good
Pio 30 mg daily
Metformin 2,000 mg daily
−0.6 (NR)−0.7 (NR)0.146
Yamanouchi 2005135
Japan
Fair
Pio 30–45 mg daily
Metformin 750 mg daily
−2.3 (NR)−2.1 (NR)NSD
Range
Fair 3
Good 2
Pio: 15–45 mg daily
Metformin: 750–2,550 mg daily
−2.3 to −0.42−2.1 to −0.47

Abbreviations: CI, confidence interval; NR, not reported; NSD, no significant difference; Pio, pioglitazone; SE, standard error; SD, standard deviation.

From: Results

Cover of Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations
Drug Class Review: Newer Diabetes Medications, TZDs, and Combinations: Final Original Report [Internet].
Jonas D, Van Scoyoc E, Gerrald K, et al.
Portland (OR): Oregon Health & Science University; 2011 Feb.
Copyright © 2011, Oregon Health & Science University.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.